Rectal INdomethacin, oral TacROlimus, or their combination for the prevention of post-ERCP pancreatitis (INTRO Trial): Protocol for a randomized, controlled, double-blinded trial

Akshintala, Venkata S.; Husain, Sohail Z.; Brenner, Todd A.; Singh, Anmol; Singh, Vikesh K.; Khashab, Mouen A.; Weiland, Christa J. Sperna; Geenen, Erwin J M van; Bush, Nikhil; Barakat, Monique T.; Shrivastava, Ananta; Kochhar, Rakesh; Talukdar, Rupjyoti; Rodge, Gajanan Ashokrao; Wu, Clement; Lakhtakia, Sundeep; Sinha, Saroj Kant; Goenka, Mahesh Kumar; Reddy, D. Nageshwar

doi:10.1016/j.pan.2022.07.008

Search citation statements

Order By: Relevance

Paper Sections

Select...

Calcium Target: Calcineurin1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Book2

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It will follow patient's post-ERCP for 30 days to assess the incidence of post-ERCP pancreatitis. [58] This trial has begun and is planned to end in December 2024.…”

Section: Calcium Target: Calcineurinmentioning

confidence: 99%

Acute pancreatitis: pathogenesis and emerging therapies

Zaman,

Gorelick

2024

Journal of Pancreatology

View full text Add to dashboard Cite

Acute pancreatitis is a severe inflammatory disorder with limited treatment options. Improved understanding of disease mechanisms has led to new and potential therapies. Here we summarize what we view as some of the most promising new therapies for treating acute pancreatitis, emphasizing the rationale of specific treatments based on disease mechanisms. Targeted pharmacologic interventions are highlighted. We explore potential treatment benefits and risks concerning reducing acute injury, minimizing complications, and improving long-term outcomes. Mechanisms associated with acute pancreatitis initiation, perpetuation, and reconstitution are highlighted, along with potential therapeutic targets and how these relate to new treatments.

show abstract

“…It will follow patient's post-ERCP for 30 days to assess the incidence of post-ERCP pancreatitis. [58] This trial has begun and is planned to end in December 2024.…”

Section: Calcium Target: Calcineurinmentioning

confidence: 99%